KindlyMD (NASDAQ:NAKA) Sees Strong Trading Volume - Should You Buy?

Key Points

• KindlyMD saw a significant increase in trading volume with over 6.7 million shares traded, marking a 115% rise from the previous session.
• Analysts from Maxim Group initiated coverage with a buy rating and a target price of $8.00, while the stock is currently trading at $2.99.
• The company reported a negative earnings per share of ($0.34) and has a market capitalization of $1.15 billion.

Shares of KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) saw unusually-high trading volume on Friday . Approximately 6,712,221 shares changed hands during mid-day trading, an increase of 115% from the previous session's volume of 3,118,135 shares.The stock last traded at $2.99 and had previously closed at $3.95.

Analyst Upgrades and Downgrades

Separately, Maxim Group initiated coverage on shares of KindlyMD in a research report on Wednesday, September 3rd. They issued a "buy" rating and a $8.00 target price for the company. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $8.00.

KindlyMD Price Performance

The company has a 50 day moving average of $8.71. The company has a market capitalization of $562.30 million, a P/E ratio of -1.74 and a beta of 33.96.

KindlyMD (NASDAQ:NAKA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.34) earnings per share for the quarter. The company had revenue of $0.41 million during the quarter. KindlyMD had a negative return on equity of 131.09% and a negative net margin of 244.00%.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.